Giovanni Vennarecci1, Gian Luca Grazi2, Isabella Sperduti3, Elisa Busi Rizzi4, Emanuele Felli5, Mario Antonini6, Giampiero D'Offizi7, Giuseppe Maria Ettorre5. 1. Division of General Surgery and Liver Transplantation, S. Camillo Hospital, Rome, Lazio, Italy. Electronic address: gvennarecci@scamilloforlanini.rm.it. 2. Division of Hepatobiliary Surgery, Regina Elena Cancer Institute, Rome, Lazio, Italy. 3. Biostatistical Unit, Regina Elena National Cancer Institute, Rome, Italy. 4. Division of Radiology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy. 5. Division of General Surgery and Liver Transplantation, S. Camillo Hospital, Rome, Lazio, Italy. 6. Intensive Care Unit, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy. 7. Hepatology and Infectious Diseases Unit, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.
Abstract
INTRODUCTION: To report our experience on associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in patients with liver tumors. METHODS: ALPPS is a surgical technique that allows hepatic resection after rapid liver hypertrophy. RESULTS: Thirteen operations were performed: 8 for hepatocellular carcinoma (HCC) with liver cirrhosis (LC) and 5 for colorectal liver metastases (CRLM, n = 3) and cholangiocarcinoma (CC, n = 2) in normal livers (NL). Of the 11 men (85%), the median age was 60 years (range 36-74). Six (75%) HCC patients had BCLC stage C and 2 (25%) had BCLC stage B disease. The median % future liver remnant (FLR) volume increase was 71.7% in patients with LC and 64.8% in NL (p = 0.44). Twelve patients achieved a sufficient FLR growth after the first stage (92.3% efficacy). Four right trisectorectomies and 9 right hepatectomies were performed. All patients completed the second stage (100% feasibility). R0 resection was achieved in all cases. The 90-day mortality rate was 23.1% (12.5% for HCC patients with LC vs 40% for CRLM and CC patients with NL, p = 0.13). After the first stage the overall morbidity rates were 62.5% and 80% (p = 0.61), whereas after the second stage they were 87.5% and 80% in patients with LC and NL respectively (p = 0.99). At a median follow-up of 15 months (range 1-27), the median DFS was 9 months (CI95% 6-12), and the 1yr-DFS was 42%. The median survival was 25 months (CI95% 10-40), and the 1-yr overall survival was 74%. CONCLUSIONS: ALPPS induced a considerable and comparable FLR growth in HCC patients with liver cirrhosis and patients with CRLM and CC with normal liver parenchyma. HCC patients who underwent ALPPS had a high rate of macrovascular tumor involvement. A high rate of R0 resection is expected in properly selected patients.
INTRODUCTION: To report our experience on associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in patients with liver tumors. METHODS: ALPPS is a surgical technique that allows hepatic resection after rapid liver hypertrophy. RESULTS: Thirteen operations were performed: 8 for hepatocellular carcinoma (HCC) with liver cirrhosis (LC) and 5 for colorectal liver metastases (CRLM, n = 3) and cholangiocarcinoma (CC, n = 2) in normal livers (NL). Of the 11 men (85%), the median age was 60 years (range 36-74). Six (75%) HCCpatients had BCLC stage C and 2 (25%) had BCLC stage B disease. The median % future liver remnant (FLR) volume increase was 71.7% in patients with LC and 64.8% in NL (p = 0.44). Twelve patients achieved a sufficient FLR growth after the first stage (92.3% efficacy). Four right trisectorectomies and 9 right hepatectomies were performed. All patients completed the second stage (100% feasibility). R0 resection was achieved in all cases. The 90-day mortality rate was 23.1% (12.5% for HCCpatients with LC vs 40% for CRLM and CC patients with NL, p = 0.13). After the first stage the overall morbidity rates were 62.5% and 80% (p = 0.61), whereas after the second stage they were 87.5% and 80% in patients with LC and NL respectively (p = 0.99). At a median follow-up of 15 months (range 1-27), the median DFS was 9 months (CI95% 6-12), and the 1yr-DFS was 42%. The median survival was 25 months (CI95% 10-40), and the 1-yr overall survival was 74%. CONCLUSIONS: ALPPS induced a considerable and comparable FLR growth in HCCpatients with liver cirrhosis and patients with CRLM and CC with normal liver parenchyma. HCCpatients who underwent ALPPS had a high rate of macrovascular tumor involvement. A high rate of R0 resection is expected in properly selected patients.
Authors: Jan Bednarsch; Zoltan Czigany; Isabella Lurje; Pavel Strnad; Philipp Bruners; Tom Florian Ulmer; Marcel den Dulk; Georg Lurje; Ulf Peter Neumann Journal: Langenbecks Arch Surg Date: 2019-11-16 Impact factor: 3.445
Authors: Resmi A Charalel; Jeffrey Sung; Gulce Askin; Jonathan Jo; Maria Mitry; Caroline Chung; Lyubov Tmanova; David C Madoff Journal: Curr Oncol Rep Date: 2021-10-30 Impact factor: 5.075
Authors: Giovanni Vennarecci; Daniele Ferraro; Antonella Tudisco; Giovanni Battista Levi Sandri; Nicola Guglielmo; Giammauro Berardi; Isabella Sperduti; Giuseppe Maria Ettorre Journal: Updates Surg Date: 2018-09-25
Authors: Eva Braunwarth; Stefan Stättner; Margot Fodor; Benno Cardini; Thomas Resch; Rupert Oberhuber; Daniel Putzer; Reto Bale; Manuel Maglione; Christian Margreiter; Stefan Schneeberger; Dietmar Öfner; Florian Primavesi Journal: Eur Surg Date: 2018-05-17 Impact factor: 0.953